Wylin R, Schneider J
Arch Surg. 1976 Jul;111(7):818-21. doi: 10.1001/archsurg.1976.01360250094020.
Improved factor VIII preparations have made major surgery feasible for hemophiliac patients, as well as increasing their survival. In a hemphoiliac undergoing prostatectomy, the effects of local or systemic fibrinolysis and possible disseminated intravascular coagulation must be considered, in addition to the factor VIII deficiency. We successfully treated an octogenarian with benign prostatic hypertrophy and mild hemophilia during and after suprapubic prostatectomy by infusions of antihemophilic factor (factor VIII) concentrate. Cessation of infusion on the 15th day resulted in bleeding two days later. This ceased after resumption of antihemophilic factor infusion. Tests for abnormal fibrinolysis and fibrin split products gave negative results.
改进的凝血因子VIII制剂使血友病患者能够进行大手术，同时也提高了他们的生存率。对于接受前列腺切除术的血友病患者，除了凝血因子VIII缺乏外，还必须考虑局部或全身纤维蛋白溶解以及可能的弥散性血管内凝血的影响。我们通过输注抗血友病因子（凝血因子VIII）浓缩物，成功地治疗了一位患有良性前列腺增生和轻度血友病的八旬老人，该患者在耻骨上前列腺切除术期间及术后均接受了治疗。在第15天停止输注后，两天后出现了出血情况。在恢复抗血友病因子输注后，出血停止。异常纤维蛋白溶解和纤维蛋白降解产物的检测结果均为阴性。
